Paras Healthcare IPO

Established Presence in Key Healthcare Markets: Paras Healthcare operates hospitals across North India, Bihar and Jharkhand. Its presence in multiple cities provides a foundation for serving patients across different regional healthcare markets.

Specialized Clinical Services: The company's focus on cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences supports its position in specialized and complex medical care. These specialties accounted for 75.30% of its revenue in FY2026.

Established Hospital Network and Brand: Operating under the Paras Health brand, the company has built a hospital network with eight facilities and 2,211 beds. Its operating history provides experience in hospital management and delivering clinical services.

Improving Financial Performance: The company reported a turnaround in profit after tax, moving from a loss of Rs. 57.98 crore in FY2025 to a profit of Rs. 43.83 crore in FY2026. EBITDA also increased during this period, indicating an improvement in reported operating performance.

Planned Capacity Expansion: Paras Healthcare plans to add hospitals in Gurugram and Ludhiana, with a target of reaching 3,011 beds by March 2028. If implemented successfully, this expansion could increase its service capacity and geographical presence.

High Borrowing Levels: Paras Healthcare reported total borrowings of Rs. 1,393.86 crore as of March 31, 2026, compared with Rs. 923.92 crore as of March 31, 2024. High debt can increase interest costs and financial obligations, potentially affecting profitability and future investment capacity.

Execution Risks in Expansion Plans: The proposed capacity expansion requires substantial investment, infrastructure development, recruitment and effective hospital management. Delays, cost overruns or slower-than-expected patient growth could affect the company's expansion targets and financial performance.

Dependence on Specialized Medical Services: CONGOR specialties contributed 75.30% of revenue in FY2026. While this concentration reflects the company's clinical focus, changes in demand, competition or operating performance in these specialties could materially affect revenue.

Inconsistent Historical Profitability: The company reported losses in FY2024 and FY2025 before returning to profitability in FY2026. Investors should evaluate whether the improvement is sustainable and whether the business can consistently generate profits across different operating conditions.

Valuation Risk: The IPO price band of Rs. 660 to Rs. 693 per share implies a significant valuation for the business. Investors should compare the company's valuation metrics with those of listed hospital operators and consider its debt, earnings consistency and future growth assumptions before investing.